Therapeutic strategy for SCD-EDS can be achieved through restoring intracellular zinc homeostasis [94], and the removal of mutant ZIP13 protein via the ubiquitin-proteasome pathway [83]. This evidence concerns the gene SLC39A13 and Schnyder corneal dystrophy.